Bionime (4737.TW) Stock Price

Bionime Price

CLOSED
56.90TWD-0.40 (-0.70 %)
Market closed

Revenue has compounded at 12.6% per year over the past 19 years to 1.84 B TWD. Earnings per share have declined at 8.4% per year over the last 16 years. Bionime's net margin stands at -9.8%, down from 4.7% several years earlier. Bionime currently offers a dividend yield of about 3.51%. The stock trades about 10% above its 52-week low.

Bionime stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bionime over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bionime stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bionime's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bionime Stock Price History
DateBionime Price
8/14/202656.90 TWD
8/13/202657.30 TWD
8/12/202657.00 TWD
8/11/202656.50 TWD
8/10/202655.80 TWD
8/7/202655.00 TWD
8/6/202654.00 TWD
8/5/202654.60 TWD
8/4/202655.00 TWD
8/3/202654.40 TWD
7/31/202656.00 TWD
7/30/202656.20 TWD
7/29/202658.00 TWD
7/28/202657.50 TWD
7/27/202657.30 TWD
7/24/202656.40 TWD
7/23/202655.40 TWD
7/22/202656.30 TWD
7/21/202655.80 TWD
7/20/202655.80 TWD
7/17/202654.80 TWD
7/16/202656.60 TWD
7/15/202658.30 TWD
7/14/202662.20 TWD
7/13/202663.60 TWD
7/10/202657.90 TWD
7/9/202657.90 TWD
7/8/202657.00 TWD
7/7/202656.90 TWD
7/6/202656.70 TWD
7/3/202656.70 TWD
7/2/202656.20 TWD
7/1/202657.20 TWD
6/30/202655.60 TWD
6/29/202657.40 TWD
6/26/202657.00 TWD
6/25/202657.10 TWD
6/24/202657.10 TWD
6/23/202657.50 TWD
6/22/202656.70 TWD
6/18/202656.90 TWD
6/17/202656.20 TWD
6/16/202655.80 TWD
6/15/202654.90 TWD
6/12/202654.90 TWD
6/11/202654.90 TWD
6/10/202654.80 TWD
6/9/202654.60 TWD
6/8/202653.70 TWD
6/5/202655.00 TWD
6/4/202654.00 TWD
6/3/202654.20 TWD
6/2/202655.00 TWD
6/1/202656.90 TWD
5/29/202657.10 TWD
5/28/202659.90 TWD
5/27/202660.00 TWD
5/26/202658.50 TWD
5/25/202656.30 TWD
5/22/202657.00 TWD
5/21/202657.50 TWD
5/20/202658.20 TWD
5/19/202658.20 TWD
5/18/202657.00 TWD
5/15/202660.60 TWD
5/14/202655.30 TWD
5/13/202658.00 TWD
5/12/202658.20 TWD
5/11/202659.40 TWD
5/8/202658.80 TWD
5/7/202658.50 TWD
5/6/202657.30 TWD
5/5/202658.20 TWD
5/4/202659.80 TWD
4/30/202662.10 TWD
4/29/202662.70 TWD
4/28/202663.00 TWD
4/27/202660.00 TWD
4/24/202661.80 TWD
4/23/202662.20 TWD
4/22/202663.00 TWD
4/21/202662.20 TWD
4/20/202663.30 TWD
4/17/202667.00 TWD
4/16/202668.90 TWD
4/15/202668.60 TWD
4/14/202668.70 TWD
4/13/202669.40 TWD
4/10/202666.90 TWD
4/9/202670.90 TWD
4/8/202670.00 TWD
4/7/202671.00 TWD
4/2/202670.30 TWD
4/1/202671.70 TWD
3/31/202667.80 TWD
3/30/202666.10 TWD
3/27/202665.10 TWD
3/26/202664.90 TWD
3/25/202664.90 TWD
3/24/202664.30 TWD
3/23/202664.00 TWD
3/20/202663.00 TWD
3/19/202662.60 TWD
3/18/202663.80 TWD
3/17/202662.00 TWD
3/16/202660.20 TWD
3/13/202660.40 TWD
3/12/202658.80 TWD
3/11/202661.10 TWD
3/10/202661.80 TWD
3/9/202660.60 TWD
3/6/202661.70 TWD
3/5/202656.50 TWD
2/26/202654.30 TWD
2/25/202654.00 TWD
2/24/202655.00 TWD
2/23/202654.40 TWD
2/11/202655.90 TWD
2/10/202654.80 TWD
2/9/202653.20 TWD
2/6/202652.70 TWD
2/5/202652.60 TWD
2/4/202651.80 TWD
2/3/202652.40 TWD
2/2/202652.50 TWD
1/30/202651.50 TWD
1/29/202655.30 TWD
1/28/202655.30 TWD
1/27/202654.00 TWD
1/26/202655.00 TWD
1/23/202654.50 TWD
1/22/202653.70 TWD
1/21/202654.00 TWD
1/20/202655.00 TWD
1/19/202656.00 TWD
1/16/202655.20 TWD
1/15/202654.90 TWD
1/14/202654.80 TWD
1/13/202654.40 TWD
1/12/202654.30 TWD
1/9/202655.20 TWD
1/8/202655.30 TWD
1/7/202655.00 TWD
1/6/202655.30 TWD
1/5/202655.70 TWD
1/2/202658.50 TWD
12/31/202559.50 TWD
12/30/202561.00 TWD
12/29/202560.00 TWD
12/26/202560.50 TWD
12/24/202559.10 TWD
12/23/202559.80 TWD
12/22/202559.00 TWD
12/19/202558.70 TWD
12/18/202559.00 TWD
12/17/202558.00 TWD
12/16/202557.00 TWD
12/15/202555.30 TWD
12/12/202555.00 TWD
12/11/202556.80 TWD
12/10/202558.00 TWD
12/9/202558.00 TWD
12/8/202558.70 TWD
12/5/202558.90 TWD
12/4/202558.50 TWD
12/3/202557.20 TWD
12/2/202557.80 TWD
12/1/202558.00 TWD
11/28/202558.80 TWD
11/27/202558.60 TWD
11/26/202558.70 TWD
11/25/202558.90 TWD
11/24/202558.60 TWD
11/21/202559.20 TWD
11/20/202560.60 TWD
11/19/202561.00 TWD
11/18/202561.10 TWD
11/17/202562.00 TWD
11/14/202562.30 TWD
11/13/202563.00 TWD
11/12/202563.20 TWD
11/11/202563.20 TWD
11/10/202564.10 TWD
11/7/202564.10 TWD
11/6/202563.50 TWD
11/5/202563.60 TWD
11/4/202562.70 TWD
11/3/202561.80 TWD
10/31/202561.60 TWD
10/30/202562.50 TWD
10/29/202563.30 TWD
10/28/202562.20 TWD
10/27/202562.20 TWD
10/23/202562.70 TWD
10/22/202562.80 TWD
10/21/202562.70 TWD
10/20/202562.50 TWD
10/17/202562.40 TWD
10/16/202562.10 TWD
10/15/202562.90 TWD
10/14/202564.00 TWD
10/13/202565.00 TWD
10/9/202563.40 TWD
10/8/202563.20 TWD
10/7/202564.10 TWD
10/3/202563.20 TWD
10/2/202563.20 TWD
10/1/202563.50 TWD
9/30/202563.20 TWD
9/26/202563.70 TWD
9/25/202563.70 TWD
9/24/202563.40 TWD
9/23/202562.70 TWD
9/22/202564.50 TWD
9/19/202566.40 TWD
9/18/202566.90 TWD
9/17/202567.70 TWD
9/16/202568.30 TWD
9/15/202569.20 TWD
9/12/202570.20 TWD
9/11/202569.00 TWD
9/10/202568.00 TWD
9/9/202567.40 TWD
9/8/202569.70 TWD
9/5/202578.30 TWD
9/4/202575.90 TWD
9/3/202575.20 TWD
9/2/202574.00 TWD
9/1/202573.70 TWD
8/29/202572.80 TWD
8/28/202572.40 TWD
8/27/202572.80 TWD
8/26/202573.00 TWD
8/25/202572.90 TWD
8/22/202572.60 TWD
8/21/202572.20 TWD
8/20/202572.20 TWD
8/19/202572.70 TWD
8/18/202573.90 TWD
Access this data via the Eulerpool API
Get Free API Key

Bionime Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
2.01 B TWD
239.30 M TWD
128.03 M TWD
Jan 1, 2019
2.17 B TWD
176.53 M TWD
106.26 M TWD
Jan 1, 2020
1.67 B TWD
75.95 M TWD
62.43 M TWD
Jan 1, 2021
1.85 B TWD
93.64 M TWD
87.41 M TWD
Jan 1, 2022
2.21 B TWD
117.13 M TWD
91.03 M TWD
Jan 1, 2023
1.76 B TWD
16.36 M TWD
6.21 M TWD
Jan 1, 2024
1.93 B TWD
-128.38 M TWD
-127.22 M TWD
Jan 1, 2025
1.84 B TWD
-197.36 M TWD
-180.28 M TWD

Bionime Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 17, 2026, 12:12 AM
 
REVENUEB TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB TWD
EBITM TWD
EBIT MARGIN%
NET INCOMEM TWD
NET INCOME GROWTH%
DIV.TWD
DIV. GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025
1.211.481.441.561.521.611.741.822.012.171.671.852.211.761.931.84
29.2421.88-2.788.71-2.315.588.144.6010.278.22-23.2010.8519.52-20.5910.14-4.91
49.3048.1743.6240.1938.9843.5744.2543.6845.6443.6544.9042.3545.4340.7439.7334.11
0.600.710.630.630.590.700.770.800.920.950.750.781.000.720.770.63
200.00193.0070.00144.00149.00189.00258.00248.00239.00176.0075.0093.00117.0016.00-128.00-197.00
16.5213.084.889.239.7811.7514.8313.6311.918.104.505.035.290.91-6.62-10.72
136.00179.0034.0089.0054.0098.00178.00149.00128.00106.0062.0087.0091.006.00-127.00-180.00
0.7431.62-81.01161.76-39.3381.4881.63-16.29-14.09-17.19-41.5140.324.60-93.41-2,216.6741.73
3.202.733.600.801.780.942.001.374.142.000.491.212.002.102.00–
–-14.6931.87-77.78122.50-47.19112.77-31.50202.19-51.69-75.50146.9465.295.00-4.76–
49.2549.1148.9149.1449.9456.1369.4363.1563.1963.8665.3866.8567.7866.8467.0767.92
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bionime generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bionime retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bionime's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bionime has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bionime's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bionime stock margins

The Bionime margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bionime. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bionime.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
45.68 %
11.92 %
6.38 %
Jan 1, 2019
43.65 %
8.12 %
4.89 %
Jan 1, 2020
44.90 %
4.55 %
3.74 %
Jan 1, 2021
42.33 %
5.06 %
4.73 %
Jan 1, 2022
45.42 %
5.30 %
4.12 %
Jan 1, 2023
40.76 %
0.93 %
0.35 %
Jan 1, 2024
39.74 %
-6.64 %
-6.58 %
Jan 1, 2025
34.15 %
-10.73 %
-9.81 %

Bionime Stock Revenue, EBIT, Earnings per Share

The Bionime earnings per share therefore indicates how much revenue Bionime has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
31.76 TWD
3.79 TWD
2.03 TWD
Jan 1, 2019
34.02 TWD
2.76 TWD
1.66 TWD
Jan 1, 2020
25.52 TWD
1.16 TWD
0.95 TWD
Jan 1, 2021
27.67 TWD
1.40 TWD
1.31 TWD
Jan 1, 2022
32.62 TWD
1.73 TWD
1.34 TWD
Jan 1, 2023
26.26 TWD
0.24 TWD
0.09 TWD
Jan 1, 2024
28.83 TWD
-1.91 TWD
-1.90 TWD
Jan 1, 2025
27.07 TWD
-2.91 TWD
-2.65 TWD

Bionime business model & stock analysis

Bionime Corp is a company that was founded in 2003 and specializes in the development and manufacture of medical devices for measuring blood sugar levels and other cardiovascular tests.

Bionime SWOT Analysis

Strengths

Bionime Corp has several strengths that contribute to its success. Firstly, the company has a strong reputation and brand image in the healthcare industry. This positive perception helps to attract customers and business partners. Moreover, Bionime Corp has a diverse portfolio of innovative and high-quality medical devices, including blood glucose monitoring systems and other diagnostic products. These cutting-edge technologies provide a competitive edge and position the company as a leader in the market. Additionally, Bionime Corp has a highly skilled and experienced workforce, enabling effective execution of its operations and the ability to develop industry-leading products.

Weaknesses

Despite its strengths, Bionime Corp does face certain weaknesses. One significant weakness is the company's limited geographical reach. Bionime Corp primarily operates in specific regions and may not have a strong presence in other markets. This limited market penetration potentially restricts the company's growth opportunities. Furthermore, Bionime Corp's heavy reliance on a few key suppliers for crucial components or materials exposes them to supply chain risks and potential disruptions. Addressing these weaknesses is crucial for the company's long-term success.

Opportunities

Bionime Corp operates in an industry with several growth opportunities. Firstly, with the increasing prevalence of chronic diseases globally, the demand for accurate diagnostic tools such as blood glucose monitoring systems is expected to rise. Bionime Corp can capitalize on this trend by expanding its market presence and introducing new products to cater to emerging markets. Additionally, advancements in healthcare technologies and the rising adoption of telemedicine provide opportunities for Bionime Corp to develop innovative solutions that integrate with digital health platforms. By embracing these opportunities, the company can achieve significant growth and enhance its competitive position.

Threats

Bionime Corp faces several threats that could impact its business. An ongoing challenge is fierce competition from other well-established healthcare companies that also offer blood glucose monitoring systems and related products. This competitive landscape puts pressure on Bionime Corp to continuously innovate and differentiate itself from rivals. Additionally, stringent regulatory requirements in the healthcare industry can create barriers to market entry and product development. Compliance with these regulations can be costly and time-consuming. Lastly, economic fluctuations and uncertainties, such as recessions or changes in healthcare policies, pose risks to Bionime Corp's revenue and profitability.

Bionime Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bionime historical P/E ratio, EBIT multiple, and P/S ratio

Bionime annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bionime shares outstanding

The number of shares of Bionime was 67.92 M in 2025. This indicates how many shares Bionime is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
63.19 M Stocks
Jan 1, 2019
63.86 M Stocks
Jan 1, 2020
65.38 M Stocks
Jan 1, 2021
66.85 M Stocks
Jan 1, 2022
67.78 M Stocks
Jan 1, 2023
66.84 M Stocks
Jan 1, 2024
67.07 M Stocks
Jan 1, 2025
67.92 M Stocks

Bionime stock splits

In Bionime's history, there have been no stock splits.

Bionime Dividend History

15 years of dividend payments

YearAnnual DividendYoY ChangePayments
20242.00TWD↓ 4.8%1×
20232.10TWD↑ 5.0%1×
20222.00TWD↑ 65.7%1×
20211.21TWD↑ 147.1%1×
20200.49TWD↓ 75.6%1×
20192.00TWD↓ 51.7%1×
20184.14TWD↑ 201.8%1×
20171.37TWD↓ 31.4%1×
20162.00TWD↑ 112.8%1×
20150.94TWD↓ 47.2%1×

Bionime dividend payout ratio

In 2025, Bionime had a payout ratio of 770.49%. The payout ratio indicates the percentage of the company's profits that Bionime distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2018
184.00 %
Jan 1, 2019
108.13 %
Jan 1, 2020
187.87 %
Jan 1, 2021
142.02 %
Jan 1, 2022
134.04 %
Jan 1, 2023
2,035.43 %
Jan 1, 2024
-94.94 %
Jan 1, 2025
770.49 %
Price targets and forecasts for Bionime are not yet available.

Bionime shareholder structure

% Name
17.08037%
Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
9.97023%
Hua Eng Wire And Cable Co Ltd
Hua Eng Wire And Cable Co Ltd
4.00155%
Huang (Chun Mu)
Huang (Chun Mu)
2.38903%
Yen Ben Investment Company Ltd.
Yen Ben Investment Company Ltd.
2.23243%
Shi (Cui E)
Shi (Cui E)
1.78336%
Shih (Chin Hsiu-a)
Shih (Chin Hsiu-a)

Bionime Beneficial Ownership Filings (SEC 13D/G)

Free Float
81.1%
Float Shares
-
Shares Outstanding
-

Bionime Executives and Management Board

14 members

Management

SH

Shixiong Huang

Deputy General Manager

–
ZX

Mr. Zhenteng Xu

Deputy General Manager-R&D

–
XZ

Xiexun Zhong

Executive Deputy General Manager

–
YC

Yawen Chen

Acting Head of Accounting

–
QH

Qianyu Huang

Head of Finance

–
WT

Wei Tang

Corporate Governance Officer

–

Board of Directors

CH

Chun Huang

Chairman of the Board, General Manager · since 2003

–
TJ

Taixiong Jiang

Deputy General Manager-Administration, Director · since 2007

–
LH

Liren Hu

Director

–
HL

Ms. Hsiu-Mei Liu

Director

–
GC

Ganren Cai

Independent Director

–
LG

Lizhen Guo

Independent Director

–

Frequently asked questions about Bionime

The business model of Bionime Corp is focused on developing and manufacturing advanced medical devices and solutions for diabetes management. They specialize in creating innovative blood glucose monitoring systems, including blood glucose meters, test strips, and other related products. Bionime Corp aims to provide accurate and reliable diabetes management tools to help individuals effectively monitor their blood sugar levels and make informed decisions about their health. With their commitment to technological advancements and quality products, Bionime Corp strives to improve the lives of people living with diabetes worldwide.

Bionime Corp primarily operates in the healthcare and medical equipment industries.

Bionime Corp faces competition from prominent players in the market such as Abbott Laboratories, Roche Holding AG, and Johnson & Johnson. These companies are also engaged in the development and manufacturing of medical devices, including glucose monitoring systems. However, Bionime Corp stands out with its innovative products and solutions, such as their blood glucose monitoring systems and diabetes management applications. With its focus on providing accurate and user-friendly products, Bionime Corp has carved a niche for itself in the market, distinguishing itself from its competitors through its commitment to high-quality healthcare solutions.

Bionime Corp is a renowned global medical technology company specializing in the development, manufacturing, and marketing of innovative healthcare products. Established in 2003, Bionime has made significant strides in the field of diabetes management. With a commitment to improving the lives of individuals living with diabetes, Bionime focuses on developing advanced blood glucose monitoring systems and related solutions. The company's expertise lies in creating user-friendly, accurate, and reliable products that empower patients to effectively manage their condition. With a strong emphasis on research and development, Bionime has emerged as a trusted brand in the healthcare industry, continuously striving for technological advancements and breakthroughs in diabetes care.

Significant milestones achieved by Bionime Corp include the development of innovative medical devices and solutions, establishing a strong global presence, and receiving numerous certifications and awards. The company has successfully launched advanced products such as blood glucose monitoring systems and continuous glucose monitoring systems, which have improved the lives of individuals managing diabetes. Bionime Corp has expanded its market reach by establishing partnerships and distribution networks in various countries. Additionally, the company has earned recognition through certifications like ISO 13485 and FDA approvals for its quality management systems. These achievements highlight Bionime Corp's commitment to enhancing healthcare and creating impactful solutions for patients worldwide.

Bionime Corp is primarily present in several countries and regions. The company has a significant presence in Taiwan, where it is headquartered. Additionally, Bionime Corp operates in various Asian markets, including China, Hong Kong, Japan, and Southeast Asian countries. It has expanded its reach to the United States, Canada, and several European countries as well. Bionime Corp's global presence allows it to serve a wide range of customers and cater to different markets' demands.

Bionime Corp represents a range of values and a corporate philosophy focused on innovation, quality, and customer satisfaction. The company is dedicated to developing advanced medical devices and solutions to meet the needs of healthcare professionals and patients. With a commitment to accuracy, reliability, and user-friendly products, Bionime Corp aims to enhance the management of diabetes and improve the overall quality of life for individuals living with the condition. By continuously investing in research and development, Bionime Corp strives to provide cutting-edge technology and personalized healthcare solutions to contribute to the well-being of its customers.

9 analysts currently rate the Bionime stock: 0 recommend buying, 3 holding and 6 selling.

Bionime Analyst Price Targets 2026

Converted at the current exchange rate, the Bionime share trades at 1.54 EUR (56.90 TWD).

Bionime Corp is a global leader in diabetes management products and medical diagnostic devices. The company, headquartered in Taiwan with branches in Europe, North America, and Asia, focuses on developing innovative measuring devices and patient management systems to improve the health of diabetes patients.

The revenue cannot currently be calculated for Bionime.

The profit cannot currently be calculated for Bionime.

The P/E ratio cannot be calculated for Bionime at the moment.

The P/S cannot be calculated for Bionime currently.

The Eulerpool Quality Score for Bionime is 1/10.

The ISIN of Bionime is TW0004737002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Bionime is 4737.TW. The ticker symbol is used to trade Bionime shares on the stock exchange.

Over the past 12 months, Bionime paid a dividend of 2.00 TWD . This corresponds to a dividend yield of about 3.51 %. For the coming 12 months, Bionime is expected to pay a dividend of 1.80 TWD.

The current dividend yield of Bionime is 3.51 %.

Bionime pays a dividend, distributed in the months of , , , .

Bionime paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 1.80 TWD are expected. This corresponds to a dividend yield of 3.16 %.

Bionime is assigned to the 'Health' sector.

To receive the latest dividend of Bionime from amounting to 2 TWD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Bionime distributed 1.89 TWD as dividends.

The dividends of Bionime are distributed in TWD.

All fundamentals and in-depth analysis of Bionime

Our stock analysis for Bionime stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionime. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bionime Stock
Bionime Revenue→
Bionime Stock
Bionime Net Income→
Bionime Stock
Bionime P/E→
Bionime Stock
Bionime P/S→
Bionime Stock
Bionime EBIT→
Bionime Stock
Bionime Dividend→
Bionime Stock
Bionime Directors Dealings→
Bionime Stock
Bionime Stocks→
Bionime Stock
Bionime Market capitalization→
Bionime Stock
Bionime Debt→
Bionime Stock
Bionime Liabilities→
Bionime Stock
Bionime Equity→
Bionime Stock
Bionime AAQS→
Bionime Stock
Bionime Employees→
Bionime Stock
Bionime ROE→
Bionime Stock
Bionime ROA→
Bionime Stock
Bionime ROCE→
Bionime Stock
Bionime News→
Bionime Stock
Bionime Analyst Price Targets→

Health Stocks

BioNoteBionik LaboratoriesBionovate TechnologiesBionetBiontechBioneerBioNxt SolutionsBionano GenomicsBiophytisBiomxBioporto A/SBiommAll Stocks A–Z →